Additional Information

Description

Paclitaxel is a chemotherapeutic agent used primarily in the treatment of various cancers, including ovarian, breast, lung, and non-small cell lung cancers. It belongs to the class of drugs known as taxanes and functions by inhibiting microtubule depolymerization, which is essential for cell division. By stabilizing microtubules and preventing their disassembly, paclitaxel interferes with the mitotic process, ultimately leading to cell death.

This formulation of paclitaxel comes in a 50 mL multiple-dose vial, with a strength of 300 mg per vial. It is administered intravenously under the supervision of a healthcare professional, with dosage and schedule determined based on the specific type of cancer being treated and the patient's overall health. Infusion times typically range from one to three hours.

Paclitaxel is highly effective for patients with advanced or metastatic cancers, where traditional treatment options may no longer be viable. However, its administration is associated with several potential side effects, including neutropenia, alopecia, nausea, vomiting, and peripheral neuropathy.